Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilene C Weitz

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Haematologica|February 17, 2022
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up resultsAlexander Roth, Wilma Barcellini, Shirley D'Sa, et al.
The New England Journal of Medicine|September 10, 2015
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal HemoglobinuriaRichard J Kelly, Britta Höchsmann, Jeff Szer, et al.
American Journal of Hematology|May 29, 2023
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin diseaseAlexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Blood|June 10, 2022
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trialAlexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Eclinicalmedicine|August 2, 2024
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BAlexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Haematologica|January 18, 2020
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky, Régis Peffault de Latour, Scott T Rottinghaus, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Haematologica|February 17, 2022
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up resultsAlexander Roth, Wilma Barcellini, Shirley D'Sa, et al.
The New England Journal of Medicine|September 10, 2015
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal HemoglobinuriaRichard J Kelly, Britta Höchsmann, Jeff Szer, et al.
American Journal of Hematology|May 29, 2023
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin diseaseAlexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Blood|June 10, 2022
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trialAlexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Eclinicalmedicine|August 2, 2024
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BAlexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Haematologica|January 18, 2020
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky, Régis Peffault de Latour, Scott T Rottinghaus, et al.
Pageof 4